Joan Merrill to Antibodies, Monoclonal
This is a "connection" page, showing publications Joan Merrill has written about Antibodies, Monoclonal.
Connection Strength
3.782
-
Why, why, why de-lupus (does so badly in clinical trials). Expert Rev Clin Immunol. 2016; 12(2):95-8.
Score: 0.453
-
Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016 Feb; 75(2):332-40.
Score: 0.440
-
Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus. Arthritis Rheum. 2012 Oct; 64(10):3364-73.
Score: 0.361
-
Safety profile and clinical activity of sifalimumab, a fully human anti-interferon a monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study. Ann Rheum Dis. 2011 Nov; 70(11):1905-13.
Score: 0.332
-
Ending the 50-year drought of FDA drug approval for SLE. Bull NYU Hosp Jt Dis. 2011; 69(3):238-42.
Score: 0.319
-
Rituximab: wanted dead or alive... Arthritis Rheum. 2010 Aug; 62(8):2188-91.
Score: 0.310
-
Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010 Jan; 62(1):222-33.
Score: 0.298
-
Gene Expression and Pharmacodynamic Changes in 1,760 Systemic Lupus Erythematosus Patients From Two Phase III Trials of BAFF Blockade With Tabalumab. Arthritis Rheumatol. 2017 03; 69(3):643-654.
Score: 0.122
-
Anifrolumab, an Anti-Interferon-a Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus. Arthritis Rheumatol. 2017 02; 69(2):376-386.
Score: 0.122
-
Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial. Ann Rheum Dis. 2017 Mar; 76(3):534-542.
Score: 0.119
-
Sifalimumab, an anti-interferon-a monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016 Nov; 75(11):1909-1916.
Score: 0.115
-
Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2014 Nov; 66(11):1653-61.
Score: 0.104
-
Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis. 2012 Nov; 71(11):1833-8.
Score: 0.088
-
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011 Dec; 63(12):3918-30.
Score: 0.085
-
A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 2009 Sep 15; 61(9):1168-78.
Score: 0.073
-
Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum. 2009 Sep 15; 61(9):1143-51.
Score: 0.073
-
What was wrong and might now go right with clinical trials for lupus? Curr Rheumatol Rep. 2009 Aug; 11(4):235-7.
Score: 0.072
-
New directions in the treatment of systemic lupus erythematosus. Curr Med Res Opin. 2009 Jun; 25(6):1501-14.
Score: 0.072
-
Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther. 2008; 10(5):R109.
Score: 0.068
-
Identification and characterization of a peptide mimetic that may detect a species of disease-associated anticardiolipin antibodies in patients with the antiphospholipid syndrome. Arthritis Rheum. 2003 Mar; 48(3):737-45.
Score: 0.046
-
Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002 Dec; 46(12):3251-8.
Score: 0.046
-
Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken). 2022 Nov; 74(11):1822-1828.
Score: 0.045
-
Two pathways of CD11b/CD18-mediated neutrophil aggregation with different involvement of protein kinase C-dependent phosphorylation. J Immunol. 1990 Oct 15; 145(8):2608-15.
Score: 0.020